Company intelligence / Profile preview

Giant Biogene Holding Co., Ltd.

Ownership: Private
Employees: ~1758
Development stage: Commercial

Overview

Giant Biogene is commercially successful with multiple products on the market. The company reported revenue of RMB3,524.1 million in 2023, representing a 49.0% increase compared to 2022, with profit of RMB1,448.2 million, a 44.6% increase from 2022[7].

Therapeutic areas: Dermatology
Modalities: Recombinant collagenRare ginsenosides
Industry: Consumable Medical Devices

Beyond the preview

Go deeper on Giant Biogene Holding Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Giant Biogene Holding Co., Ltd..

Explore the full profile